Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Price

Showing results (51-60 of 184) with videos related to

Pageof 19
Sort By:
Chest|June 18, 2002
Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionateElizabeth F Juniper, David B Price, Patti A Stampone, et al.
NPJ Primary Care Respiratory Medicine|October 30, 2019
Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort studyDavid B Price, Jaco Voorham, Guy Brusselle, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
Biologics in severe asthma: the role of real-world evidence from registriesGiovanni Paoletti, Jack Pepys, Marta Casini, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 16, 2022
Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance TherapyStephanie Chen, Marc Miravitlles, Chin Kook Rhee, et al.
Allergy|July 11, 2018
Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthmaJaco Voorham, Xiao Xu, David B Price, et al.
NPJ Primary Care Respiratory Medicine|June 24, 2016
UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational studyDavid B Price, Glenis Scadding, Claus Bachert, et al.
Drugs|November 22, 2019
Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β<sub>2</sub>-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary CareDavid B Price, Victoria Carter, Jessica Martin, et al.
American Journal of Respiratory and Critical Care Medicine|September 17, 2019
Systematic Literature Review of Systemic Corticosteroid Use for Asthma ManagementEugene R Bleecker, Andrew N Menzies-Gow, David B Price, et al.
BMJ Open|March 9, 2023
Individualised risk prediction model for exacerbations in patients with severe asthma: protocol for a multicentre real-world risk modelling studyTae Yoon Lee, Mohsen Sadatsafavi, Chandra Prakash Yadav, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2016
ReplyWillem M C van Aalderen, Jonathan Grigg, Theresa W Guilbert, et al.
Pageof 19

Showing results (51-60 of 184) with videos related to

Sort By:
Pageof 19
Chest|June 18, 2002
Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionateElizabeth F Juniper, David B Price, Patti A Stampone, et al.
NPJ Primary Care Respiratory Medicine|October 30, 2019
Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort studyDavid B Price, Jaco Voorham, Guy Brusselle, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
Biologics in severe asthma: the role of real-world evidence from registriesGiovanni Paoletti, Jack Pepys, Marta Casini, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 16, 2022
Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance TherapyStephanie Chen, Marc Miravitlles, Chin Kook Rhee, et al.
Allergy|July 11, 2018
Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthmaJaco Voorham, Xiao Xu, David B Price, et al.
NPJ Primary Care Respiratory Medicine|June 24, 2016
UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational studyDavid B Price, Glenis Scadding, Claus Bachert, et al.
Drugs|November 22, 2019
Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β<sub>2</sub>-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary CareDavid B Price, Victoria Carter, Jessica Martin, et al.
American Journal of Respiratory and Critical Care Medicine|September 17, 2019
Systematic Literature Review of Systemic Corticosteroid Use for Asthma ManagementEugene R Bleecker, Andrew N Menzies-Gow, David B Price, et al.
BMJ Open|March 9, 2023
Individualised risk prediction model for exacerbations in patients with severe asthma: protocol for a multicentre real-world risk modelling studyTae Yoon Lee, Mohsen Sadatsafavi, Chandra Prakash Yadav, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2016
ReplyWillem M C van Aalderen, Jonathan Grigg, Theresa W Guilbert, et al.
Pageof 19